Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (361-370 of 438) with videos related to

Pageof 44
Sort By:
Virchows Archiv : an International Journal of Pathology|October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entitiesKatharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Lancet (London, England)|August 9, 2025
Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialFabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
Respiration; International Review of Thoracic Diseases|March 1, 2022
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest PhysiciansMarek Lommatzsch, Klaus F Rabe, Christian Taube, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 TrialsRoy S Herbst, Hen Prizant, Daniel Ruderman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung CancerRamaswamy Govindan, Aleksandra Szczesna, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideStephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Pageof 44

Showing results (361-370 of 438) with videos related to

Sort By:
Pageof 44
Virchows Archiv : an International Journal of Pathology|October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entitiesKatharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Lancet (London, England)|August 9, 2025
Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trialFabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2023
SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung CancerCharles M Rudin, Stephen V Liu, Ross A Soo, et al.
Respiration; International Review of Thoracic Diseases|March 1, 2022
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest PhysiciansMarek Lommatzsch, Klaus F Rabe, Christian Taube, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2025
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 TrialsRoy S Herbst, Hen Prizant, Daniel Ruderman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2017
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung CancerRamaswamy Govindan, Aleksandra Szczesna, Myung-Ju Ahn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2023
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposideStephen V Liu, Tony S K Mok, Barzin Y Nabet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Nir Peled, Shiruyeh Schokrpur, et al.
Pageof 44